

Corrigendum to ‘Weight change and clinical outcomes in heart failure with reduced ejection fraction: Insights from EMPEROR-Reduced’ [*Eur J Heart Fail* 2023;25:117–127]

Under the section ‘Weight change’ on page 122 of the original version of this manuscript, the data for empagliflozin and placebo were not presented correctly and have been corrected, so it reads as:

‘In patients with baseline peripheral oedema, body weight nominally decreased more than in patients without peripheral oedema, but there was no difference between the treatment groups - the adjusted mean change from baseline to week 12 in those with oedema and treated with empagliflozin was -1.17 kg (95% confidence interval [CI] -1.63 to -0.72) versus -0.90 kg (95% CI -1.37 to -0.43) in those on placebo. In patients without oedema at baseline, changes of body weight were -0.68 kg (95% CI -0.86 to -0.50) in those treated with empagliflozin and $+0.29$ kg (95% CI 0.11 – 0.47) in patients on placebo’.